Table 2.

Adjuvant chemoradiotherapy

Author/trial	Study period	No. of PDAC patients	Regimen	MST	Hazard ratio	p
Kalser/GITSG	1974–1982	43	5-FU + RT vs. no adjuvant treatment	OS: 20.0 vs. 11.0 M	–	0.035
Klinkenbijl/EORTC 40891	1987–1995	114	5-FU + RT vs. no adjuvant treatment	OS: 17.1 vs. 12.6 M	–	0.099
Neoptolemos/ESPAC-1	1994–2000	289	5-FU + RT vs. no adjuvant treatment	OS: 15.9 vs. 17.9 M	1.28	0.053
Regine/RTOG9704	1998–2002	451	5-FU + RT + GEM vs. 5-FU + RT	OS: 18.8 vs. 16.7 M	0.79	0.047

Phase III trials of adjuvant CRT